MedPath

A comparative study between two materials in the promotion of liver growth before liver surgery

Not Applicable
Completed
Conditions
iver cancer
Cancer
Malignant neoplasm of liver and intrahepatic bile ducts
Registration Number
ISRCTN16062796
Lead Sponsor
Centro Hospitalar Universitário Lisboa Central
Brief Summary

2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33825512/ (added 09/09/2021)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria

1. Diagnosis of primary or secondary malignant tumours of the liver, documented by computed tomography or magnetic resonance imaging or biopsy of the tumor lesion
2. Indication for resection of the hepatic tumor
3. An estimated future liver remnant (FLR) less than:
3.1. 25% in healthy liver
3.2. 40% in cirrhotic liver or with severe steatosis or previous chemotherapy
4. Renal function suitable for the use of iodinated venous contrast medium:
4.1. Serum creatinine = 1.4 mg/dL
4.2. Clearance of creatinine (GFR) = 60 mL/min/1.73m2
5. Age = 18 years

Exclusion Criteria

1. Uncorrectable coagulopathies
2. Sectorial portal thrombosis (e.g., thrombosis of the right anterior sectorial branch)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hepatic hypertrophy (liver volume growth) measured by computed tomography volumetry at 14 and 28 days
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath